Cited by 251Medication Adherence and ComplianceBreast Cancer Treatment StudiesCancer survivorship and care

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Adherence to Endocrine Therapy for Breast Cancer

Chlebowski, Rowan T., Geller, Michelle L.·2006·Oncology

Open this paper in CoChat — free account

Abstract

Purpose: Despite the demonstrated efficacy of long-duration adjuvant tamoxifen and aromatase inhibitor use in breast cancer management, information on adherence to such therapy is limited. Therefore, we reviewed the published literature regarding hormonal therapy adherence in clinical trial and practice settings. Methods: A systematic search of the PubMed database, augmented by a review of manuscript references and conference proceedings, commonly identified adherence reports in clinical trials but identified only 9 adherence reports in clinical practice settings. Results: In adjuvant breast cancer clinical trials with longer (≧4 years) follow-up, hormonal therapy (tamoxifen or aromatase inhibitors) was prematurely discontinued by about 23–28% of the study participants. Adherence to aromatase inhibitors did not differ from adherence to tamoxifen in this setting. In breast cancer prevention trials, tamoxifen was prematurely discontinued by 20–46% of the participants. In clinical practice settings, only 2 reports addressed longer-duration (>4 years) adherence to adjuvant tamoxifen use. In these, tamoxifen was prematurely discontinued by 30–50% of the patients. Conclusion: Adherence to prescribed breast cancer hormone therapy has not received concerted attention. Current, albeit limited, evidence suggests long-term hormone therapy adherence may represent an area limiting optimal breast cancer patient treatment.

Integrity signals

Registry

Crossref · 10.1159/000100444

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Adherence to medication.
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L. D., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,456
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759

Show all 50 references

Research works printed but not linked: 1

10.1016%2FS0140-6736%2805%2974803-0 · DOI

Sorted by citations

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
Hershman, D. L., Kushi, L. H., Shao, T. H., Buono, D. L., Kershenbaum, A., Tsai, W., Fehrenbacher, L., Gomez, S. L., Miles, S. Q., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 834
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Malin, J. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 799
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ziller, V., Kalder, M., Albert, U., Holzhauer, W., Ziller, M., Wagner, U. A. G., & Hadji, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn646 · Cited by 263
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Goss, P. E., Ingle, J. N., Pritchard, K. I., Ellis, M. J., Sledge, G. W., Budd, G. T., Rabaglio, M., Ansari, R., Johnson, D. B., Tozer, R. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7805 · Cited by 257
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8619 · Cited by 244
Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
Chlebowski, R. T., Kim, J., & Haque, R. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0389 · Cited by 195
Self-citation
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
Cuzick, J. M., Šestak, I., Cella, D. F., & Fallowfield, L. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70259-6 · Cited by 188
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer
Sedjo, R. L., & Devine, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0952-6 · Cited by 176
Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor–Associated Arthralgia Syndrome
Morales, L., Pans, S., Verschueren, K., CALSTER, B. V., Paridaens, R., Westhovens, R., Timmerman, D., SMET, L. D., Vergote, I. B., Christiaens, M.-R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4005 · Cited by 150
Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review
Roberts, M. C., Wheeler, S. B., & Reeder-Hayes, K. E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2014.302490 · Cited by 142
Influence of Patient and Treatment Factors on Adherence to Adjuvant Endocrine Therapy in Breast Cancer
Bender, C. M., Gentry, A. L., Brufsky, A. M., Casillo, F. E., Cohen, S. M., Dailey, M. M., Donovan, H. S., Dunbar-Jacob, J., Jankowitz, R. C., Rosenzweig, M. Q., et al. (2014) · Oncology Nursing Forum · doi:10.1188/14.onf.274-285 · Cited by 131
Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
Hadji, P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.02.001 · Cited by 137
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
Partridge, A. H., Archer, L. E., Kornblith, A. B., Gralow, J. R., Grenier, D., Perez, E. A., Wolff, A. C., Wang, X., Kastrissios, H., Berry, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4671 · Cited by 128
Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review
Lambert, L. K., Balneaves, L. G., Howard, A. F., & Gotay, C. C. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4561-5 · Cited by 134
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study
Wigertz, A., Ahlgren, J., Holmqvist, M., Fornander, T., Adolfsson, J., Lindman, H., Bergkvist, L., & Lambe, M. P. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1961-4 · Cited by 123
Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator
Wills, S. M., Ravipati, A., Venuturumilli, P., Kresge, C. L., Folkerd, E. J., Dowsett, M., Hayes, D. F., & Decker, D. A. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000352 · Cited by 121
Household Net Worth, Racial Disparities, and Hormonal Therapy Adherence Among Women With Early-Stage Breast Cancer
Hershman, D. L., Tsui, J., Wright, J. D., Coromilas, E. J., Tsai, W. Y., & Neugut, A. I. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3062 · Cited by 121
Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial
Sjöström, M., Lundstedt, D., Hartman, L. W., Holmberg, E. C., Killander, F., Kovács, A., Malmström, P., Niméus, E., Rönnerman, E. W., Fernö, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7263 · Cited by 117
Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer
Farias, A. J., & Du, X. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2807 · Cited by 109
The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer
Hershman, D. L., Tsui, J., Meyer, J., Glied, S., Hillyer, G. C., Wright, J. D., & Neugut, A. I. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju319 · Cited by 104
Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer
Nekhlyudov, L., Li, L., Ross‐Degnan, D., & Wagner, A. K. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1703-z · Cited by 99
Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
Hackshaw, A. K., Roughton, M., Forsyth, S., Monson, K., Reczko, K., Sainsbury, R., & Baum, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2933 · Cited by 99
Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer
Brett, J., Fenlon, D., Boulton, M., Hulbert-Williams, N. J., Walter, F. M., Donnelly, P., Lavery, B., Morgan, A., Morris, C., & Watson, E. (2018) · European Journal of Cancer Care · doi:10.1111/ecc.12601 · Cited by 98
Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.
Foulon, V., Schöffski, P., & Wolter, P. (2011) · PubMed · doi:10.2143/acb.66.2.2062525 · Cited by 99
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
Dent, S. F., Gaspo, R., Kissner, M., & Pritchard, K. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1351-3 · Cited by 90
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., Skaar, T. C., Nguyen, A., Desta, Z., Storniolo, A. M., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.14 · Cited by 86
Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review
Hurtado-de-Mendoza, A., Cabling, M. L., Lobo, T., Dash, C., & Sheppard, V. B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.006 · Cited by 79
Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer
Friese, C. R., Pini, T. M., Li, Y., Abrahamse, P. H., Graff, J. J., Hamilton, A. S., Jagsi, R., Janz, N. K., Hawley, S. T., Katz, S. J., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2499-9 · Cited by 89
Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention
Lin, J., Zhang, S. M., & Manson, J. E. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0380 · Cited by 83
Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review
Banning, M. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01295.x · Cited by 83
Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study
Ziller, V., Kyvernitakis, I., Knöll, D., Storch, A., Hars, O., & Hadji, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-407 · Cited by 82
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
Ciruelos, E., Pascual, T., Vozmediano, M. L. A., Blanco, M., Manso, L., Parrilla, L., Muñoz, C., Vega, E., Calderón, M. J., Sancho, B., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.01.016 · Cited by 82
Treatment decision-making in breast cancer: the patient–doctor relationship
Fallowfield, L. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0077-3 · Cited by 80
Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer
Neugut, A. I., Zhong, X., Wright, J. D., Accordino, M. K., Yang, J., & Hershman, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1291 · Cited by 78
Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow-up
Simon, R., Latreille, J., Matte, C., Desjardins, P., & Bergeron, É. (2014) · Canadian Journal of Surgery · doi:10.1503/cjs.006211 · Cited by 75
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy
Kimmick, G., Edmond, S. N., Bosworth, H. B., Peppercorn, J., Marcom, P. K., Blackwell, K., Keefe, F. J., & Shelby, R. A. (2015) · The Breast · doi:10.1016/j.breast.2015.06.010 · Cited by 72
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Din, O. S., Dodwell, D. J., Wakefield, R. J., & Coleman, R. E. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0757-7 · Cited by 72
Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence
Heisig, S. R., Mora, M. C. S., von Blanckenburg, P., Schuricht, F., Rief, W., Albert, U., & Nestoriuc, Y. (2014) · Psycho-Oncology · doi:10.1002/pon.3611 · Cited by 72
Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis
Fontein, D. B. Y., Seynaeve, C., Hadji, P., Hille, E. T. M., van de Water, W., Putter, H., Kranenbarg, E. M., Hasenburg, A., Paridaens, R., Vannetzel, J.-M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3068 · Cited by 71
Adherence to hormone therapy among women with breast cancer
Brito, C., Portela, M. C., & de Vasconcellos, M. T. L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-397 · Cited by 74
Mobile Apps and Quality of Life in Patients With Breast Cancer and Survivors: Systematic Literature Review
Saevarsdottir, S. R., & Gudmundsdottir, S. L. (2023) · Journal of Medical Internet Research · doi:10.2196/42852 · Cited by 68
Interruption and Non-Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome of Breast Cancer Women - An Asian Population-Based Study
Hsieh, K., Chen, L., Cheung, K., Chang, C.-S., & Yang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087027 · Cited by 72
Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer
Xu, S., Yang, Y., Tao, W., Song, Y., Chen, Y., Ren, Y., Liu, J., & Pang, D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2286-z · Cited by 67
Adherence to Oral Endocrine Therapy for Breast Cancer: A Nursing Perspective
Miaskowski, C. A., Shockney, L. D., & Chlebowski, R. T. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.213-221 · Cited by 67
Self-citation
Adherence to long-term adjuvant hormonal therapy for breast cancer
Gotay, C. C., & Dunn, J. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.80 · Cited by 65
Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients
Arriola, K. J., Mason, T. A., Bannon, K. A., Holmes, C. E., Powell, C. L., Horne, K., & O'Regan, R. M. (2014) · Patient Education and Counseling · doi:10.1016/j.pec.2013.12.019 · Cited by 63
Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic
Wong, S., Bounthavong, M., Nguyen, C., Bechtoldt, K., & Hernandez, E. A. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130278 · Cited by 62
Endocrine Therapy Use Among Elderly Hormone Receptor-Positive Breast Cancer Patients Enrolled in Medicare Part D
Riley, G. F., Warren, J. L., Harlan, L. C., & Blackwell, S. A. (2011) · Medicare & Medicaid Research Review · doi:10.5600/mmrr.001.04.a04 · Cited by 58
Implementing a Low-Fat Eating Plan in the Women's Intervention Nutrition Study
Hoy, M. K., Winters, B., Chlebowski, R. T., Papoutsakis, C., Shapiro, A. C., Lubin, M. P., Thomson, C. A., Grosvenor, M. B., Copeland, T., Falk, E., et al. (2009) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.12.016 · Cited by 58
Self-citation
Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
Güth, U., Huang, D. J., Schötzau, A., Zanetti‐Dällenbach, R., Holzgreve, W., Bitzer, J., & Wight, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604525 · Cited by 58
Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model
Shingler, S. L., Bennett, B. M., Cramer, J. A., Towse, A., Twelves, C., & Lloyd, A. J. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.952715 · Cited by 55
Age-Specific Nonpersistence of Endocrine Therapy in Postmenopausal Patients Diagnosed with Hormone Receptor–Positive Breast Cancer: A TEAM Study Analysis
van de Water, W., Bastiaannet, E., Hille, E. T. M., Kranenbarg, E. M., Putter, H., Seynaeve, C., Paridaens, R., de Craen, A. J. M., Westendorp, R. G. J., Liefers, G., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0037 · Cited by 55
Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors
Nekhlyudov, L., Madden, J. M., Graves, A. J., Zhang, F., Soumerai, S. B., & Ross‐Degnan, D. (2011) · Journal of Cancer Survivorship · doi:10.1007/s11764-011-0188-4 · Cited by 54
Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients
Wouters, H., van Dijk, L., Geers, H. C. J., Winters, N. A., van Geffen, E. C. G., Stiggelbout, A. M., & Bouvy, M. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146272 · Cited by 54
Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study
Beer, B., Schubert, B., Oberguggenberger, A., Meraner, V., Hubalek, M., & Oberacher, H. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4075-z · Cited by 52
Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?
Wuensch, P. H., Hahne, A., Haidinger, R., Meißler, K., Tenter, B., Stoll, C., Senf, B., & Hübner, J. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1779-z · Cited by 53
High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
Fontein, D. B. Y., Nortier, J. W. R., Liefers, G., Putter, H., Kranenbarg, E. M., Bosch, J., Maartense, E., Rutgers, E. J. T., & van de Velde, C. J. H. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.11.010 · Cited by 50
Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study
Bluethmann, S. M., Murphy, C. C., Tiro, J. A., Mollica, M. A., Vernon, S. W., & Bartholomew, L. K. (2017) · Oncology nursing forum · doi:10.1188/17.onf.e101-e110 · Cited by 50
Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
Güth, U., Myrick, M. E., Schötzau, A., Kilic, N., & Schmid, S. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1668-y · Cited by 51
Compliance and persistence of endocrine adjuvant breast cancer therapy
Güth, U., Myrick, M. E., Kilic, N., Eppenberger‐Castori, S., & Schmid, S. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1801-y · Cited by 49
Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence
Wouters, H., Stiggelbout, A. M., Bouvy, M. L., Maatman, G. A., Van Geffen, E. C. G., Vree, R., Nortier, J. W., & Van Dijk, L. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.04.005 · Cited by 46
Reasons for Nonadherence to Tamoxifen and Aromatase Inhibitors for the Treatment of Breast Cancer: A Literature Review
Sawesi, S., Carpenter, J. S., & Jones, J. (2014) · Clinical journal of oncology nursing · doi:10.1188/14.cjon.e50-e57 · Cited by 47
The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees
Neuner, J. M., Kamaraju, S., Charlson, J. A., Wozniak, E. M., Smith, E. C., Biggers, A., Smallwood, A. J., Laud, P. W., & Pezzin, L. E. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv130 · Cited by 47
Impact of Multifocality and Lymph Node Metastasis on the Prognosis and Management of Microinvasive Breast Cancer
Kapoor, N. S., Shamonki, J. M., Sim, M., Chung, C. T., & Giuliano, A. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2924-7 · Cited by 43
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects
Oberguggenberger, A., Sztankay, M. J., Beer, B., Schubert, B., Meraner, V., Oberacher, H., Kemmler, G., Giesinger, J. M., Gamper, E., Sperner‐Unterweger, B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-474 · Cited by 45
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer
Chlebowski, R. T., Cuzick, J. M., Amakye, D. D., Bauerfeind, I., Buzdar, A. U., Chia, S., Cutuli, B., Linforth, R., Maass, N., Noguchi, S., et al. (2009) · The Breast · doi:10.1016/s0960-9776(09)70002-5 · Cited by 43
Self-citation
Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study
Shelton, R. C., Hillyer, G. C., Hershman, D. L., Leoce, N., Bovbjerg, D. H., Mandelblatt, J. S., Kushi, L. H., Lamerato, L. E., Nathanson, S. D., Ambrosone, C. B., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2370-4 · Cited by 43
Does fasting during Ramadan trigger non-adherence to oral hormonal therapy in breast cancer patients?
Zeeneldin, A. A., Gaber, A. A., & Taha, F. M. (2012) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2012.06.003 · Cited by 42
The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients
Farias, A. J., Hansen, R. N., Zeliadt, S. B., Ornelas, I. J., Li, C. I., & Thompson, B. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000351 · Cited by 41
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
Jabbour, E. J., Saglio, G. N., Radich, J. P., & Kantarjian, H. M. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.04.002 · Cited by 40
Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer
Wouters, H., Maatman, G. A., van Dijk, L., Bouvy, M. L., Vree, R., van Geffen, E. C. G., Nortier, J. W. R., & Stiggelbout, A. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt195 · Cited by 39
Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status
Farias, A. J., & Du, X. L. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0280 · Cited by 40
Adherence with adjuvant hormonal therapy for breast cancer
Ruddy, K. J., & Partridge, A. H. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp039 · Cited by 37
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
Gjerde, J., Gandini, S., Guerrieri‐Gonzaga, A., Moi, L. L. H., Aristarco, V., Mellgren, G., DeCensi, A., & Lien, E. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2074-9 · Cited by 36
Oral Endocrine Therapy Nonadherence, Adverse Effects, Decisional Support, and Decisional Needs in Women With Breast Cancer
Milata, J. L., Otte, J. L., & Carpenter, J. S. (2016) · Cancer Nursing · doi:10.1097/ncc.0000000000000430 · Cited by 35
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer
Scott, S., Brown, M. A., & Come, S. E. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.595560 · Cited by 32
Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia
Getachew, S., Addissie, A., Seife, E., Wakuma, T., Unverzagt, S., Jemal, A., Taylor, L., Wienke, A., & Kantelhardt, E. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyac081 · Cited by 31
Chemoprevention for breast cancer
Božović‐Spasojević, I., de Azambuja, E., McCaskill‐Stevens, W., Dinh, P., & Cardoso, F. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.005 · Cited by 32
A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL)
Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L. E., Buono, D. L., Nathanson, D. S., Bovbjerg, D. H., Mandelblatt, J. S., Tsai, W., Jacobson, J. S., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3855-3 · Cited by 34
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial
Sadigh, G., Gray, R. J., Sparano, J. A., Yanez, B. R., Garcia, S. F., Timsina, L., Sledge, G. W., Cella, D. F., Wagner, L. I., & Carlos, R. C. (2021) · Cancer · doi:10.1002/cncr.33527 · Cited by 30
Options for early breast cancer follow-up in primary and secondary care - a systematic review
Taggart, F. M., Donnelly, P. K., & Dunn, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-238 · Cited by 29
Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors
Emerson, M. A., Achacoso, N. S., Benefield, H. C., Troester, M. A., & Habel, L. A. (2021) · Cancer · doi:10.1002/cncr.33423 · Cited by 29
Racial/Ethnic Differences in Use and Duration of Adjuvant Hormonal Therapy for Breast Cancer in the Women's Health Initiative
Livaudais, J. C., LaCroix, A. Z., Chlebowski, R. T., Li, C. I., Habel, L. A., Simon, M. S., Thompson, B., Erwin, D. O., Hubbell, F. A., & Coronado, G. D. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1225 · Cited by 29
Self-citation
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)
Ruddy, K. J., Pitcher, B., Archer, L. E., Cohen, H. J., Winer, E. P., Hudis, C. A., Muss, H. B., & Partridge, A. H. (2012) · Annals of Oncology · doi:10.1093/annonc/mds133 · Cited by 28
Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions
Humphries, B., Collins, S., Guillaumie, L., Lemieux, J., Dionne, A. R., Provencher, L., Moisan, J., & Lauzier, S. (2018) · Pharmacy · doi:10.3390/pharmacy6020053 · Cited by 31
Oral Chemotherapy Medications: The Need for a Nurse's Touch
Winkeljohn, D. L. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.793-796 · Cited by 28
Psychometric properties of the Beliefs about Medicine Questionnaire–adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer
Brett, J., Hulbert-Williams, N., Fenlon, D., Boulton, M. G., Walter, F. M., Donnelly, P., Lavery, B. A., Morgan, A. A., Morris, C., Horne, R., et al. (2017) · Health Psychology Open · doi:10.1177/2055102917740469 · Cited by 26
Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
Gao, P., You, L., Wu, D., Shi, A., Miao, Q., Rana, U., Martin, D. P., Du, Y., Zhao, G., Han, B., et al. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s167004 · Cited by 27
Patient Adherence to Aromatase Inhibitor Treatment in the Adjuvant Setting
Verma, S., Madarnas, Y., Sehdev, S. R., Martin, G., & Bajcar, J. (2011) · Current Oncology · doi:10.3747/co.v18i0.899 · Cited by 27
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
Li, L., Chang, B., Jiang, X., Fan, X., Li, Y., Li, T., Wu, S., Zhang, J., Kariminia, S., & Li, Q. (2018) · BMC Cancer · doi:10.1186/s12885-018-4878-4 · Cited by 27
The Breast Cancer Quality of Care Study (BQUAL): A Multi-Center Study to Determine Causes for Noncompliance with Breast Cancer Adjuvant Therapy
Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L. E., Nathanson, S. D., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., Magai, C., Tsai, W. Y., et al. (2012) · The Breast Journal · doi:10.1111/j.1524-4741.2012.01240.x · Cited by 25
Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy
Dorfman, C. S., Arthur, S. S., Kimmick, G. G., Westbrook, K. E., Marcom, P. K., Corbett, C. M., Edmond, S. N., & Shelby, R. A. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001337 · Cited by 25
Cost‐effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population
Noah‐Vanhoucke, J., Green, L. E., Dinh, T., Alperin, P., & Smith, R. A. (2011) · Cancer · doi:10.1002/cncr.25926 · Cited by 26
Low Adherence to Upfront and Extended Adjuvant Letrozole Therapy among Early Breast Cancer Patients in a Clinical Practice Setting
Lee, H. S., Lee, J., Ah, Y.-M., Kim, H. S., Im, S., Noh, D., & Lee, B. K. (2014) · Oncology · doi:10.1159/000360702 · Cited by 26
Hurdles and delays in access to anti-cancer drugs in Europe
Ades, F. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.482 · Cited by 25
Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ
Livaudais, J. C., Hwang, E. S., Karliner, L., Nápoles, A. M., STEWART, S. L., Bloom, J. R., & Kaplan, C. P. (2011) · Journal of Women s Health · doi:10.1089/jwh.2011.2773 · Cited by 24

Authors: Chlebowski, R. T., & Geller, M. L.
Affiliations: The Lundquist Institute (US)
ORCID: Chlebowski, Rowan T.
Venue: Oncology
Publisher: S. Karger AG
Published: 2006
Volume: 71
Issue: 1-2
Pages: 1-9
ISSN: 0030-2414 (ISSN-L)
1423-0232
DOI: 10.1159/000100444
OpenAlex: W1540562253
Cited by: 251
References: 50
Citations by year: 2026: 5 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 6 · 2017: 9 · 2016: 12 · 2015: 9 · 2014: 21 · 2013: 14 · 2012: 22
FWCI: 3.00
Type: journal article
Language: en
Open access: closed
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords: medication adherence, breast cancer, adjuvant endocrine therapy, tamoxifen, aromatase inhibitors, premature discontinuation, Breast Cancer Prevention Trial
MeSH terms: Administration, Oral, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Patient Compliance, Tamoxifen, Antineoplastic Agents, Hormonal, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adherence to Endocrine Therapy for Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks